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Abstract: Familial hypercholesterolemia is an autosomally dominant disorder caused by 
various mutations in low-density lipoprotein receptor genes. This will lead to elevated levels 
of total and low-density lipoprotein cholesterol, which may in turn lead to   premature coronary 
atherosclerosis and cardiac-related death. The symptoms are more severe in the homozygous 
type of the disease. Different options for the treatment of affected patients are now available. 
Diet therapy, pharmacologic therapy, lipid apheresis, and liver transplantation are among the 
various treatments. We clinically review the treatment and   management strategies for the disease 
in order to shed light on the optimal management of familial hypercholesterolemia.
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Introduction
Familial hypercholesterolemia is a genetic autosomal dominant disorder caused by 
various mutations in low-density lipoprotein (LDL) receptor gene, which is located 
on chromosome 19. The more than 700 mutations can cause defects in LDL receptors 
which are located mainly in the liver.1,2 The main function of LDL receptors is removing 
the LDL particles from the plasma by endocytosis.1 Various degrees of such defects 
can cause different symptom severities. The most severe form is related to total lack 
of receptors (receptor-negative mutations), while ‘receptor-defective’ mutations that 
comprise most of the mutations are usually accompanied by lesser symptoms.1 The 
mutations differ in various populations leading to a variety of symptoms and severity 
in different countries.3–6
These mutations lead to the specific phenotype of familial hypercholesterolemia. 
There are two other genes whose mutations can cause a similar phenotype; the gene 
related to apolipoprotein B-100 and the newly recognized proprotein convertase 
subtilisin/kexin type 9.
The consequences of such defects in LDL receptor genes are changes in vascular 
endothelial function,7 high total serum cholesterol (usually more than 290 mg/dL; 
7.5 mmol/L), and high serum LDL (usually above 190 mg/dL; 4.9 mmol/L). The 
values in children may vary, but hypercholesterolemia usually lead to atherosclerotic 
changes in coronary arteries, as well as formation of tendon xanthomas.1 Familial 
hypercholesterolemia is also associated with increased peripheral arterial diseases, as 
well as increased thickness of intima media of femoral and carotid arteries, although 
reviews have shown that more evidence is needed to link a conclusive associa-
tion between this disease and risk of stroke.8 Tendon xanthomas that are caused by Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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deposition of high cholesterol in tendons and skin are seen in 
elbows, knees, Achilles tendon, hands, and other parts of the 
body (Figures 1 and 2). Tendon xanthoma is highly sugges-
tive of familial hypercholesterolemia and is a basic criterion 
in the clinical diagnosis of this disease. In some studies, about 
one-third of patients with familial hypercholesterolemia had 
displayed xanthomas, although up to 50% of such patients 
can be affected.9 It has been shown that tendon xanthomas 
are associated with increased risk of cardiovascular disease 
independent of gene mutation. Moreover, the risk in women 
is much higher than men. This warrants the need for caution 
and start to lipid-lowering management as early as possible in 
when such xanthomas are defected.9 Excessive cholesterol can 
also deposit in the cornea, causing corneal arcus (Figure 3).
There are two types of familial hypercholesterolemia; 
heterozygous and homozygous. The mode of inheritance of 
the heterozygous type is autosomal dominant. The incidence 
of the former type is about 1 in 500, and signs of hypercholes-
terolemia, including coronary heart disease and xanthomas, 
are usually presented in patients older than 20 years.2 The 
homozygous type of the disease, which is an autosomal 
codominant disorder, has an incidence of one in a million and 
is usually presented in earlier years of life accompanied by 
more severe signs and symptoms leading to coronary artery 
bypass grafting (CABG) in the second decade of life.10–12
Involvement of the cardiac valve is another important and 
serious complication in the natural course of the disease.13 
The aortic valve is usually involved, and this can be indepen-
dent of the atherosclerotic changes in the coronary arteries as 
the involvement of the aortic valve in the presence of intact 
grafted coronary vessels has been reported.14
Treatment options
Various treatment options have been proposed to manage 
familial hypercholesterolemia.15,16 Each has some advantages 
and disadvantages (Table 1). The options include changes 
in lifestyle and diet regulation, pharmacologic therapy with 
different categories of drugs affecting various pathways of 
cholesterol absorption and metabolism and invasive proce-
dures including lifelong lipid apheresis, and finally, liver 
transplantation.
Dietary treatment
There is a recommendation from the American Heart Asso-
ciation that, dietary treatment should be added to other 
pharmacological treatments in children and adolescents.17 
Figure 1 Xanthoma in volar surface of left hand in a patient with homozygous 
familial hypercholesterolemia.
Figure  2  Xanthoma  of  Achilles  tendon  in  a  patient  with  homozygous  familial 
hypercholesterolemia.
Figure  3  Corneal  arcus  eye  in  a  patient  with  homozygous  familial  hypercho-
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Dovepress 
Dovepress
1081
Optimal management of familial hypercholesterolemia
Dietary   interventions in some countries aim to reduce fat, 
saturated fatty acids, and cholesterol intake and to consider 
carbohydrates to compensate for the low energy caused by 
low-fat diet.2 For patients with risk factors, saturated fatty acids 
are restricted to a maximum of 7% of total calorie intake and 
dietary cholesterol to 200 mg/day.18 Along with the positive 
effects of the diet, some problems including lower intake of fat-
soluble vitamins and lower levels of HDL as well as an increase 
in triglycerides caused by high carbohydrate intake may occur. 
Recommendations include using normal total fat intake and 
increasing some dietary components including omega-3 fatty 
acids and soy protein.17 However, a recent review on the 
effectiveness of such dietary intervention reported no definite 
conclusion because of the lack of adequate data.2
For children with LDL .190 mg/dL (4.9 mmol/L), it is 
unlikely that dietary treatment alone can lower the choles-
terol level to an acceptable concentration; however, dietary 
  intervention should be a major part of any long-term   treatment 
because it can lead to a lower dose of   pharmacologic drugs.18
Pharmacologic treatments
There is strong evidence that atherosclerotic changes begin 
in childhood and the severity of lipid abnormalities leads to 
increase in such changes. The first evidence came from the 
autopsies done on soldiers killed during wars, including the 
Vietnam War. A survey on those autopsies showed that about 
half of the young soldiers with a mean age of 22 years had 
evidence of coronary atherosclerosis and some were severely 
affected.19 It would be rational to start aggressive treatment 
in early ages to reach the treatment goal of ,130 mg/dL 
(3.4 mmol/L) or ,110 mg/dL (2.8 mmol/L) in those with 
other risk factors.17,18 The epidemic of   obesity in children 
in most developed countries makes the   treatment neces-
sary. Besides, as the lifestyle changes are not   sufficiently 
effective,17 it is recommended that in children older than 
10 years, along with a dietary intervention, some sort of drug 
should be started to   control the high blood cholesterol level 
in those having LDL .160 mg/dL (4.1 mmol/L) with fam-
ily history of coronary artery disease or LDL .190 mg/dL 
(4.9 mmol/L) without such history.20 A recent  recommenda-
tion by the National Cholesterol Education Program notes 
that even in adult patients with 0–1 risk factors and LDL 
cholesterol level of 160–189 mg/dL, drug therapy can be 
considered after a trial of lifestyle change. For those patients 
with LDL $190 mg/dL, drug therapy is recommended.21
Various drugs have been proposed for such purposes. All 
have advantages and disadvantages.
Bile acid sequestrants
Use of bile acid sequestrants such as cholestyramine showed 
that they only have minor effects on lowering cholesterol 
levels.22 Besides, their tolerability was a major concern. 
Liacouras et al reported that most of the children they 
treated with cholestyramine discontinued the drug after 
about 22 months of treatment because of   gastrointestinal 
side effects.23
Fenofibrate from the fibrate class is another drug with the 
license for use in children.2 It works by activating the peroxi-
some proliferator-activated receptor type alpha. Fenofibrate 
was assumed to be able to lower LDL. However, Tonstad 
reported that there was little evidence for its   effectiveness in 
children, although it was well tolercated.24
Statin therapy
The other category of drugs that have been used effectively in 
adults with hypercholesterolemia are hydroxymethylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors.25–27 Statins 
have also shown favorable results and safety profile in 
Table 1 Comparison of various treatment modalities in familial hypercholesterolemia
Characteristics Advantages Disadvantages
Diet Reduced fat, saturated fatty acids, and 
cholesterol intake. Consider carbohydrates  
to compensate the low energy caused by  
low-fat diet
Need to lower doses  
of pharmacologic drugs
Lower intake of fat-soluble vitamins, 
lower levels of HDL, and increase in 
triglycerides
Drugs Can decrease LDL and triglycerides,  
or increase HDL
effective blood cholesterol  
control
Drug-specific side effects
Lipid apheresis For homozygous patients or heterozygous  
nonresponsive to drug therapy
Rapid LDL decrease to 40%–60% 
retards the progression of  
intima-media thickness
invasiveness, rebound LDL 
increase, no availability in all 
centers
Liver transplantation Treatment of choice for patients who  
are not responsive to routine  
pharmacologic treatments
Transfer a rich source of  
functioning LDL receptors,  
resolution of the symptoms
Long-term immunosuppression, lack 
of facility in most centers, restricted 
donors
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  adolescents, although response to these drugs is reported 
to be dependent on LDL receptor genotype.28,29 It was 
reported that the response to statins in decreasing the LDL 
and   apolipoprotein B was affected by the class of mutation. 
Patients with class V mutations, in whom the internalized 
LDL particles cannot be released into the endosomes1, show 
a higher decrease in LDL and apolipoprotein B levels after 
treatment with statins.30 This finding was contrary to the 
results of Sun et al who reported that patients with severe 
mutations had higher LDL cholesterol during treatment with 
simvastatin,31 while Sijbrands et al reported similar lipid- 
lowering response in heterozygous patients with either mRNA-
positive or mRNA-negative LDL   receptor mutations.32
A prominent effect of statins is that they can improve 
endothelial dysfunction caused by hypercholesterolemia.33 
Along with their benefits, some side effects including myo-
pathy have been reported.34–36 For new users, a   threefold 
increase in the risk of myopathy has been reported for women, 
while such risk for men is about sixfold. In addition, the 
risk is different in various ethnicities.35 The drugs are also 
contraindicated in pregnancy because of the possible side 
effects on the fetus.
Statin therapy: lovastatin
Lovastatin is an effective inhibitor of HMG-CoA reductase, 
which catalyzes the conversion of hydroxymethylglutarate 
to mevalonate. This is a rate-limiting step in the process of 
cholesterol synthesis.37 The effect of lovastatin to decrease 
serum total or LDL cholesterol was reported to be similar in 
patients with different gene mutations. Vuorio et al reported 
that lovastatin efficacy was similar in patients with Helsinki 
gene compared with patients having North Karelia gene.38
In a double-blind, randomized, placebo-controlled study, 
Clauss et al compared the efficacy of diet plus two different 
doses of lovastatin (20 and 40 mg/day) with diet plus placebo 
in a group of adolescent girls with heterozygous familial 
hypercholesterolemia.37 They reported that lovastatin at doses 
up to 40 mg/day could reduce LDL and total   cholesterol. They 
also reported good   tolerability of lovastatin in their group of 
adolescent girls with hypercholesterolemia.37
Statin therapy: pravastatin
The efficacy and safety of statins have been reported in some 
other studies.39–41 The US Food and Drug Administration has 
approved prescribing pravastatin for treatment of heterozy-
gous familial hypercholesterolemia in children older than 
8 years.42 Wiegman et al reported a 2-year study of such 
parameters in children and adolescents with heterozygous 
familial hypercholesterolemia treated with pravastatin.28 
Although there was a concern about the long-term effects 
of statins in the growth and sexual development of children 
treated with such drugs, they reported no adverse effects 
on these aspects as well as on hormone levels or muscular 
or liver tissues. They assessed the safety by measuring the 
carotid intima-media thickness before and after the treat-
ment, which showed a trend toward regression after treatment 
with pravastatin compared with the placebo group. Similar 
results regarding the safety and tolerability of pravastatin 
was reported by Hedman et al, although they reported 
that the efficacy was insufficient in children with severe 
hypercholesterolemia.42
Statin therapy: rosuvastatin
Rosuvastatin, another HMG-CoA reductase inhibitor, has 
been prescribed in adults with hypercholesterolemia with 
favorable effects.43 Its effects in children were assessed also in 
a large, multicenter, double-blind, placebo-controlled study.44 
The researchers compared the various doses of rosuvastatin 
(5–20 mg/day) with placebo in a group of pubertal patients 
(10–17 years old) with heterozygous familial hypercholes-
terolemia in 20 centers around Europe and North America. 
A maximum of 20 mg rosuvastatin daily could reduce LDL 
by 50%; however, only 40% of the patients could achieve the 
LDL serum level ,110 mg/dL (2.8 mmol/L) recommended 
for children with hypercholesterolemia accompanied by 
other risk factors.18,44 This study showed that statin therapy 
in children could be safe.
Statin therapy: simvastatin
Simvastatin is another member of this drug family. Its 
effect on patients with the heterozygous disease type who 
had different types of mutations in LDL receptor genes was 
assessed by Heath et al.45 In accordance with Sun et al31 
they reported that, of their patients with severe mutations, 
fewer achieved optimal LDL cholesterol compared with their 
control group of patients with mild mutations. They found 
that this difference was statistically significant at 40 mg/day 
of simvastatin.45
Statin therapy: meta-analyses
Meta-analyses of articles that studied statins in the   treatment 
of familial hypercholesterolemia reported the same results. 
Arambepola et al analyzed 18 articles, which were matched 
with their search criteria;46 11 were trials, including 8 random-
ized controlled trials, and the remaining 7 were case series. 
Their meta-analysis showed an overall 32% reduction in LDL Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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cholesterol and 1.9 mmol/L   absolute reduction in LDL after 
treatment with various types of statins including lovastatin, 
pravastatin, simvastatin, and atorvastatin in children aged 
8–18 years with heterozygous   familial   hypercholesterolemia. 
Statins could also increase HDL by 3.4% but had no sig-
nificant effect on   reduction of triglycerides.46 Based on such 
findings, they finally   concluded that statin monotherapy is 
safe, well tolerated, and   efficacious. However, long-term 
safety was still a concern.
Another systematic review of statin therapy in   children 
with heterozygous familial hypercholesterolemia was 
reported by Avis et al who analyzed six randomized, 
  double-blind, placebo-controlled trials evaluating various 
types of statins.27 The statins included atorvastatin, pravasta-
tin, simvastatin, and lovastatin. They reported that treatment 
with statins led to significant reduction in total cholesterol, 
LDL, and apolipoprotein B. HDL was increased after treat-
ment, but there was no significant difference between the 
treated groups and the placebo groups in adverse effects 
such as muscle toxicity, sexual development, and liver toxic-
ity. They suggested using statin treatment for children with 
heterozygous familial hypercholesterolemia, although they 
recommended that further assessment of lifelong safety was 
  needed.27
In the homozygous type, a main cause of mortality and 
morbidity is aortic stenosis rather than   involvement of the 
coronary arteries. A direct relation between aortic stenosis 
and hypercholesterolemia has been reported.47 It was also 
shown that aortic stenosis can be developed many years after 
bypass graft and even with antilipid treatment.14
Statins combined with other drugs
Some other medications have been proposed to add to statins 
to enhance their effectiveness.48,49 Ezetimibe, a selective 
inhibitor of cholesterol absorption, binds to a protein called 
Niemann-Pick C1 like 1, which is located at the brush border 
membrane of enterocytes, and contributes to intestinal uptake 
of cholesterol.50 The effects of combined treatment of statins 
and ezetimibe have been reported to reduce LDL up to 20% in 
some studies.49,51 In a randomized, double-blind, multicenter 
trial on adults with hypercholesterolemia, Kastelein et al 
compared the effects of treatment with simvastatin with either 
placebo or 10-mg ezetimibe in a group of patients during a 
2-year period.50 They measured the intima-media thickness 
of carotid and femoral arteries as well as the changes in the 
blood levels of LDL, triglycerides, and C-reactive protein. 
Although they reported no difference between the intima-
media thickness of carotid and femoral arteries between the 
two groups, they found significant reduction in LDL, trig-
lycerides, and C-reactive protein after combined treatment 
with ezetimibe.50 More effectiveness can be achieved by 
adding other drugs such as niacin as it has been reported that 
combined treatment with simvastatin/ezetimibe and niacin 
had had superior effects in reduction of LDL compared with 
simvastatin/ezetimibe or niacin-alone treatment in patients 
with hyperlipidemia.52
Pharmacotherapeutic need for newer 
drugs
Still there are concerns that the optimal goals for   treatment of 
hypercholesterolemia might be hard to achieve. As reported 
by Avis et al, only 40% of their patients achieved the 
treatment goal.44 Reports from other countries highlight 
the same concern. Pijlman et al reported that only 21% of 
the patients with heterozygous   hypercholesterolemia in the 
Netherlands achieved the treatment goal, which   required new 
medical options to be combined with current   treatments.53 
Mipomersen, a second-generation antisense   oligonucleotide, 
can inhibit the synthesis of   apolipoprotein B-100, which 
is an essential component of all atherogenic lipoproteins 
such as LDL and has been used to lower cholesterol level 
in patients with   hypercholesterolemia.54 In a multicenter, 
randomized, double-blind,   placebo-controlled trial, Raal et al 
used mipomersen to treat patients with homozygous familial 
hypercholesterolemia older than 12 years who were already 
receiving maximum tolerated doses of lipid-lowering drugs.55 
They injected 200 mg mipomersen subcutaneously every 
week for 26 weeks to a treatment group and compared them 
with those who received placebo. Mipomersen reduced LDL 
levels by a mean of 25% and by an absolute reduction of more 
than 2.5 mmol/L. It could also increase the HDL concentra-
tion by about 15%. Although there were some side effects 
including mild erythema of the injection site and influenza 
like symptoms, they introduced mipomersen as a novel and 
effective treatment to be added to other drugs for refractory 
hypercholesterolemia.55
Lipid apheresis
Lipid apheresis is an accepted method for treating patients 
with heterozygous familial hypercholesterolemia who are 
unresponsive to pharmacologic therapy or for those with 
the homozygous disease type. It is now considered the treat-
ment of choice for the latter group of patients.56 It is advised 
to combine apheresis with maximum-tolerated doses of 
statins plus ezetimibe.48 As the LDL receptors in patients 
with homozygous familial hypercholesterolemia are mostly Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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not functional, such patients usually do not respond well to 
routine antilipid treatments such as statins whose main func-
tion is upregulating LDL receptors in the liver.55
There are various methods for lipid apheresis;57 it is usu-
ally performed to lower the LDL level by 40%–60%.58 But 
there will be a rebound in the LDL level after each session. 
The nature of the cholesterol rebound differs in different 
individuals. It is very fast in normal individuals, slower in 
patients with heterozygous hypercholesterolemia, and slow-
est in patients with the homozygous disease type.59 After 2 
weeks, patients with heterozygous types will return to the 
baseline level, while this period for homozygous patients is 
about 3–4 weeks. That is why fortnightly sessions of apheresis 
in homozygous patients lead to a reduction of cholesterol in a 
larges percentage compared with the heterozygous patients. 
Regular sessions of apheresis lead to lower levels of cho-
lesterol after rebounds.59 LDL apheresis can also retard the 
progression of intima-media thickness.60
For effective apheresis, two good veins are required; 
For patients with poor venous access, an atriovenous fistula 
should be performed.61 Long-term effects of lipid apheresis 
in homozygous patients have been reported, although there 
are concerns about the expenses and the invasiveness of 
the procedure.55,61 In addition, it is not a procedure that is 
  available in all centers.10,12
Thompson and colleagues recommend that the target 
level for homozygous patients who receive lipid apheresis 
should be an acute reduction in LDL .70% or in total 
cholesterol .65% after each session. They also sug-
gest a baseline of total   cholesterol ,9 mmol/L or LDL 
,8.5 mmol/L.59
Liver transplantation
Operative strategies to reduce blood cholesterol have been 
proposed previously. However, as it is known that most of 
the LDL receptors are located in the liver, this procedure 
has become a treatment of choice for affected patients non 
responsive to routine pharmacologic   treatments.10,12,62,63 
Although there is always a concern about long-term immuno-
suppression, the lack of facilities in most centers, as well as 
restricted donors,55 and improvements in surgical techniques 
and immunologic approaches, have led to favorable outcomes 
after transplantation.64
The transplanted liver retains the specific qualities of the 
donor, so liver transplantation can transfer a rich source of 
functioning LDL receptors to the recipient, which may lead 
to a cure of the hypercholesterolemia and resolution of the 
symptoms. However, the success of this type of treatment 
depends on the total functional receptors transplanted; hence, 
to the graft size.64 That is why auxiliary liver grafts cannot 
be used for such patients. Having considered that there are 
other sources of LDL receptors in the body rather than the 
liver, complementary treatments after transplantation may 
be needed in some severely affected patients.65
Hypercholesterolemia, if untreated, finally will lead to 
severe cardiac disease. Successful combined heart and liver 
transplantation has been reported earlier.66,67 However,   it is 
currently, recommended that liver transplantation should be 
done before end-stage cardiac disease necessitates a heart 
transplant.64
Surgical management of affected 
heart and vascular system
Hypercholesterolemia can affect heart and vascular system 
by deposition of cholesterol in coronary arteries, heart valves, 
and carotid arteries. In the homozygous type, the symptoms 
present in early years of life.10–12,14
Cardiac involvement
In many cases, such patients present first with cardiac symp-
toms, and through screening, their hyperlipidemia may be 
discovered. It is recommended that any child with positive 
family history and risk factors who presented with chest pain 
should be extensively evaluated. Exercise tolerance test is 
positive in such patients, and coronary angiography should 
be done to demonstrate the extent of coronary involvement, 
which is usually in an advanced stage. The left main coronary 
artery is usually affected, and CABG is the preferred treat-
ment option instead of percutaneous coronary intervention. 
After considering the lower ages of patients with homozygous 
hypercholesterolemia, the choice of conduits for grafting is 
arterial; however, favorable results have been reported from 
venous grafts.11,12
If a compromised heart might endanger patients during 
a major operative procedure such as liver transplantation, 
cardiac surgery before transplantation is recommended.68 
We recommend performing CABG before liver transplan-
tation because of the advanced stage of coronary artery 
disease and involvement of left main coronary artery 
compromise the heart.
Carotid involvement
Other than coronary arteries, carotid arteries are most prone to 
obstruction caused by cholesterol deposition; however, because 
of the larger caliber than the coronary arteries, carotids may 
be affected in the later decades of life. We have previously Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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operated on a 14-year-old patient with homozygous type.14 
During the long-term follow-up of the patient, we found that 
both his carotids were obstructed at the age of 24 years (10 
years after the CABG). Treatment of such obstructions in the 
carotid can be performed by stenting.
Aortic involvement
Ascending aorta and the valve are two other common struc-
tures of the heart that can be affected. Atherosclerotic changes 
in the wall of the ascending aorta lead to supravalvular steno-
sis, and deposition of cholesterol on the aortic valve may 
lead to aortic stenosis. Such aortic valve involvement can be 
present even without coronary involvement. In our previously 
reported case, the patient’s aortic valve was affected after 
5 years of CABG while neither his grafted vessels nor the 
native ones were affected during that period.14 Management 
of aortic involvement can be pharmacologic or surgical, 
depending on the severity of the disease. Favorable effects of 
using statins to slow the progression of aortic stenosis have 
been reported,69 although their efficacy has been attributed 
to some degree to their anti-inflammatory effects.70 In case 
5 of severe aortic stenosis, aortic valve replacement, which 
is accompanied by favorable outcome, is recommended in 
such patients.14
After the CABG or aortic replacement, in patients with 
homozygous type for whom the pharmacologic treatment is 
not effective, liver transplantation must be performed as soon 
as possible to prevent the recurrence of hypercholesterolemic 
changes in the grafted vessels or the replaced aorta.
Screening
As familial hypercholesterolemia is an autosomal   dominant 
genetic disorder with full penetrance, it is logical that a patient 
with the disease will have some other affected relatives in 
his/her family.71 Bhatnagar et al reported that they found 
121 new patients by screening and cholesterol testing 200 
relatives of patients with heterozygous familial hypercho-
lesterolemia.72 Having considered the 1/500 frequency of the 
heterozygous type in European countries, this ratio of patients 
could be detected in a population-based study by   performing 
as large as 60,000 tests. Guidelines of   screening for   familial 
  hypercholesterolemia still follow the rules released by the 
expert panel in 1992.17,20 The panel recommended two 
approaches: a population-based approach to modify the fat 
intake and a targeted screening approach to find people with 
high LDL who need further management. However, there was 
a concern about universal screening because it was believed 
that this approach might label some children as having a 
‘disease’, hence, selective screening was recommended for 
those children and adolescents with family history of a parent 
aged ,55 years who had coronary, peripheral, or cerebral 
vascular atherosclerosis or a parent with sudden cardiac death, 
myocardial infarction, or previous coronary artery operations.17   
For the children screened, their lipid profile should be checked 
twice and lifestyle and dietary changes should be started 
when LDL levels are high. Drug therapy should be started 
for children with persistent elevated LDL (.190 mg/dL) 
who are not responsive to diet therapy or for children with 
LDL .160 mg/dL (4.1 mmol/L) accompanied by at least two 
other risk factors.17 Children with diabetes mellitus should 
receive drugs if their LDL blood level exceeds 130 mg/dL 
(3.4 mmol/L).18
It is also recommended to focus on the pregnancy period 
of women with hypercholesterolemia. The lipid profile of the 
partner should be checked, and if he is found to be hypercho-
lesterolemic, utero-genetic evaluation should be performed 
to find out if the fetus has the homozygous type.61
The future
Considering the serious side effects of hypercholesterolemia 
and its considerable rate of mortality and morbidity, novel 
methods for treating the disease are steadily sought by 
researchers. Gene therapy may be a remedy for this dis-
ease.73 Raper et al reported that liver-directed ex vivo gene 
therapy can be done safely in selected patients.74 Others 
used different methods, including adenovirus gene transfer, 
to study the function of lipoprotein receptors.75 Human 
amniotic epithelial cells as a transgene carrier has been 
reported as a favorable approach for gene therapy in patients 
with familial hypercholesterolemia.76 New improvements in 
methods of gene therapy have increased the hope of reaching 
an optimal management of familial hypercholesterolemia 
in future.77
Conclusion
Familial hypercholesterolemia is a serious genetic dis-
order affecting patients in the early years of life. Early 
diagnosis and optimal management is crucial to prevent 
the high rate of mortality and morbidity caused by the 
disease. Various treatment options are available at the 
moment. Diet and pharmacologic therapies are the first 
steps. Statins have shown favorable effects in various 
trails. They are effective both in adults and children. Inva-
sive procedures such as LDL apheresis are reserved for 
homozygous-type patients or for heterozygous patients 
who are not responsive to routine drug therapy. Liver Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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transplantation is the last resort for treating such patients.   
It has the capability to replenish the body with functional 
LDL receptors, which may lead to a cure of the disease.
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